1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Urinary Tract Infections - Pipeline Review, H1 2015

Urinary Tract Infections - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 137 pages

Urinary Tract Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Urinary Tract Infections - Pipeline Review, H1 2015’, provides an overview of the Urinary Tract Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Urinary Tract Infections - Pipeline Review, H1 2015
Table of Contents
Introduction 9
Global Markets Direct Report Coverage 9
Urinary Tract Infections Overview 10
Therapeutics Development 11
Pipeline Products for Urinary Tract Infections - Overview 11
Pipeline Products for Urinary Tract Infections - Comparative Analysis 12
Urinary Tract Infections - Therapeutics under Development by Companies 13
Urinary Tract Infections - Therapeutics under Investigation by Universities/Institutes 16
Urinary Tract Infections - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Urinary Tract Infections - Products under Development by Companies 20
Urinary Tract Infections - Products under Investigation by Universities/Institutes 23
Urinary Tract Infections - Companies Involved in Therapeutics Development 24
Achaogen Inc. 24
Adenium Biotech ApS 25
AstraZeneca PLC 26
ConjuGon, Inc. 27
Cubist Pharmaceuticals, Inc. 28
Da Volterra 29
DexTech Medical AB 30
FOB Synthesis, Inc. 31
GlycoVaxyn AG 32
Melinta Therapeutics, Inc 33
Merck and Co., Inc. 34
MerLion Pharmaceuticals Pte Ltd 35
Nabriva Therapeutics AG 36
NovaBay Pharmaceuticals, Inc. 37
Nymox Pharmaceutical Corporation 38
Osel Inc. 39
Paratek Pharmaceuticals, Inc. 40
Sequoia Sciences, Inc. 41
Shionogi and Co., Ltd. 42
Syntiron LLC 43
Tetraphase Pharmaceuticals Inc. 44
The Medicines Company 45
Urinary Tract Infections - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
(ceftaroline fosamil + avibactam sodium) - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
(ceftazidime + avibactam sodium) - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
(meropenem+ RPX-7009) - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
AA-139 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
auriclosene - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
C-1205 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
CatDex - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
cefepime - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
DAV-210 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
delafloxacin - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
Drugs to Inhibit COX-2 for Urinary Tract Infections - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
EBX-002 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
eravacycline - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Escherichia coli vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
extraintestinal pathogenic escherichia coli vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
finafloxacin - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
FSI-1686 - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
GP-4 - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
klebsiella pneumoniae vaccine - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
LACTIN-V - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
Micselon - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
Nu-2 - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
Nu-3 - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
NXB-4221 - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
omadacycline - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
plazomicin sulfate - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
Proteins for Infectious Diseases - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
relebactam - Drug Profile 96
Product Description 96
Mechanism of Action 96
RandD Progress 96
S-649266 - Drug Profile 98
Product Description 98
Mechanism of Action 98
RandD Progress 98
Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
Vaccine for Urinary Tract Infection - Drug Profile 100
Product Description 100
Mechanism of Action 100
RandD Progress 100
ZTI-01 - Drug Profile 101
Product Description 101
Mechanism of Action 101
RandD Progress 101
Urinary Tract Infections - Recent Pipeline Updates 102
Urinary Tract Infections - Dormant Projects 125
Urinary Tract Infections - Discontinued Products 127
Urinary Tract Infections - Product Development Milestones 128
Featured News and Press Releases 128
Jan 08, 2015: MerLion's Finafloxacin Shows Positive Phase 2 Results in Complicated Urinary Tract Infections 128
Dec 19, 2014: FDA approves new antibacterial drug Zerbaxa 129
Dec 05, 2014: Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 129
Oct 08, 2014: Tetraphase Pharmaceuticals Announces Presentation of Data at IDWEEK on the Activity of Eravacycline Against Multidrug-Resistant Bacteria 130
Oct 06, 2014: Tetraphase Pharmaceuticals Announces Initiation of Pivotal Portion of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI 131
Sep 04, 2014: Merck's Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA 132
Sep 02, 2014: Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion 132
Jul 28, 2014: Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 133
Jul 01, 2014: GlycoVaxyn announces the initiation of a Phase I clinical trial in collaboration with Janssen for a vaccine against Extra-intestinal pathogenic Escherichia coli causing urinary tract infection 134
Jun 19, 2014: Cubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

List of Tables

Number of Products under Development for Urinary Tract Infections, H1 2015 11
Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Products under Development by Companies, H1 2015 (Contd..2) 22
Products under Investigation by Universities/Institutes, H1 2015 23
Urinary Tract Infections - Pipeline by Achaogen Inc., H1 2015 24
Urinary Tract Infections - Pipeline by Adenium Biotech ApS, H1 2015 25
Urinary Tract Infections - Pipeline by AstraZeneca PLC, H1 2015 26
Urinary Tract Infections - Pipeline by ConjuGon, Inc., H1 2015 27
Urinary Tract Infections - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 28
Urinary Tract Infections - Pipeline by Da Volterra, H1 2015 29
Urinary Tract Infections - Pipeline by DexTech Medical AB, H1 2015 30
Urinary Tract Infections - Pipeline by FOB Synthesis, Inc., H1 2015 31
Urinary Tract Infections - Pipeline by GlycoVaxyn AG, H1 2015 32
Urinary Tract Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 33
Urinary Tract Infections - Pipeline by Merck and Co., Inc., H1 2015 34
Urinary Tract Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2015 35
Urinary Tract Infections - Pipeline by Nabriva Therapeutics AG, H1 2015 36
Urinary Tract Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 37
Urinary Tract Infections - Pipeline by Nymox Pharmaceutical Corporation, H1 2015 38
Urinary Tract Infections - Pipeline by Osel Inc., H1 2015 39
Urinary Tract Infections - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 40
Urinary Tract Infections - Pipeline by Sequoia Sciences, Inc., H1 2015 41
Urinary Tract Infections - Pipeline by Shionogi and Co., Ltd., H1 2015 42
Urinary Tract Infections - Pipeline by Syntiron LLC, H1 2015 43
Urinary Tract Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 44
Urinary Tract Infections - Pipeline by The Medicines Company, H1 2015 45
Assessment by Monotherapy Products, H1 2015 46
Assessment by Combination Products, H1 2015 47
Number of Products by Stage and Target, H1 2015 49
Number of Products by Stage and Mechanism of Action, H1 2015 51
Number of Products by Stage and Route of Administration, H1 2015 53
Number of Products by Stage and Molecule Type, H1 2015 55
Urinary Tract Infections Therapeutics - Recent Pipeline Updates, H1 2015 102
Urinary Tract Infections - Dormant Projects, H1 2015 125
Urinary Tract Infections - Dormant Projects (Contd..1), H1 2015 126
Urinary Tract Infections - Discontinued Products, H1 2015 127

List of Figures

Number of Products under Development for Urinary Tract Infections, H1 2015 11
Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Products, H1 2015 19
Assessment by Monotherapy Products, H1 2015 46
Assessment by Combination Products, H1 2015 47
Number of Products by Top 10 Targets, H1 2015 48
Number of Products by Stage and Top 10 Targets, H1 2015 48
Number of Products by Top 10 Mechanism of Actions, H1 2015 50
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 50
Number of Products by Top 10 Routes of Administration, H1 2015 52
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 52
Number of Products by Top 10 Molecule Types, H1 2015 54
Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Benzyl alcohol is an aromatic alcohol, which is metabolized into benzoic acid inthe human body. Benzyl alcohol is manufactured by hydrolysis of benzyl chloride in the presence of soda ash through the toluene ...

Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Global Feed Antibiotics Market

October 2016 $ 4250

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.